Impact of treatment reduction for childhood acute lymphoblastic leukemia on serum immunoglobulins and antibodies against vaccine-preventable diseases

Pediatric Blood and Cancer

Volumn 58, Issue 5, 2012, Pages 701-707

  van Tilburg, Cornelis M ^a   Bierings, Marc B ^a   Berbers, Guy A M ^b   Wolfs, Tom F W ^a   Pieters, Rob ^c,d   Bloem, Andries C ^a   Sanders, Elisabeth A M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Acute lymphoblastic leukemia; Child; Immunodeficiency; Immunoglobulins; Secondary specific antibodies; Toxicity

Indexed keywords

ANTIBODIES,ANTISERA AND IMMUNOGLOBULINS; ANTIBODY; BORDETELLA PERTUSSIS ANTIBODY; DIPHTHERIA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; BORDETELLA PERTUSSIS; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXIN; FEMALE; HUMANS; IMMUNOGLOBULINS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TETANUS TOXIN; VACCINES;

EID: 84857809164     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23258     Document Type: Article

References (29)

1. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
2. Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
3. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010; 24: 309-319.
4. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
5. Lehrnbecher T, Koehl U, Wittekindt B, et al. Changes in host defence induced by malignancies and antineoplastic treatment: Implication for immunotherapeutic strategies. Lancet Oncol 2008; 9: 269-278.
6. de Vaan GA, van Munster PJ, Bakkeren JA. Recovery of immune function after cessation of maintenance therapy in acute lymphoblastic leukemia (ALL) of childhood. Eur J Pediatr 1982; 139: 113-117.
7. Caver TE, Slobod KS, Flynn PM, et al. Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 619-622.
8. Luczynski W, Stasiak-Barmuta A, Krawczuk-Rybak M. Immunologic monitoring of maintenance therapy for acute lymphoblastic leukaemia in children-preliminary report. Pediatr Blood Cancer 2004; 42: 416-420.
9. Eyrich M, Wiegering V, Lim A, et al. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia-A prospective study of 20 paediatric patients. Br J Haematol 2009; 147: 360-370.
10. Ek T, Mellander L, Hahn-Zoric M, et al. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and haemophilus influenzae type b. J Pediatr Hematol Oncol 2004; 26: 727-734.
11. van Tilburg CM, Sanders EA, Rovers MM, et al. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: A systematic review. Leukemia 2006; 20: 1717-1722.
12. Patel SR, Ortin M, Cohen BJ, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007; 44: 635-642.
13. Zengin E, Sarper N. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination. Pediatr Blood Cancer 2009; 53: 967-972.
14. Esposito S, Cecinati V, Brescia L, et al. Vaccinations in children with cancer. Vaccine 2010; 28: 3278-3284.
15. van der Does-van den Berg A, Hermans J, Nagel J, et al. Immunity to diphtheria, pertussis, tetanus, and poliomyelitis in children with acute lymphocytic leukemia after cessation of chemotherapy. Pediatrics 1981; 67: 222-229.
16. Patel SR, Chisholm JC, Heath PT. Vaccinations in children treated with standard-dose cancer therapy or hematopoietic stem cell transplantation. Pediatr Clin North Am 2008; 55: 169-186, xi.
17. Fioredda F, Cavillo M, Banov L, et al. Immunization after the elective end of antineoplastic chemotherapy in children. Pediatr Blood Cancer 2009; 52: 165-168.
18. Winick N. Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed? Pediatr Blood Cancer 2009; 53: 922-923.
19. van Tilburg CM, Sanders EA, Nibbelke EE, et al. Impact of reduced chemotherapy treatment for good risk childhood acute lymphoblastic leukaemia on infectious morbidity. Br J Haematol 2011; 152: 433-440.
20. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2008; CD006501.
21. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
22. van Lier EA, Oomen PJ, Oostenbrug MW, et al. High vaccination coverage of the National Immunization Programme in the Netherlands. Ned Tijdschr Geneeskd 2009; 153: 950-957.
23. Hendrikx LH, Berbers GA, Veenhoven RH, et al. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: Effect of vaccine antigen content. Vaccine 2009; 27: 6530-6536.
24. de Vries E, Kuijpers TW, van Tol MJ, et al. Immunology in medical practice. XXXIV. Screening for suspected immunodeficiency: Introduction. Ned Tijdschr Geneeskd 2000; 144: 2192-2196.
25. van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008; 335: 79-89.
26. van der Klis FR, Mollema L, Berbers GA, et al. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 2009; 67: 301-308.
27. Steens A, Mollema L, Berbers GA, et al. High tetanus anti-toxin concentrations in the Netherlands: A sero-epidemiological study. Vaccine 2010; 28: 7803-7809.
28. van Tilburg CM, van der Velden VH, Sanders EA, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: Impact on lymphocyte compartment composition. Leuk Res 2011; 35: 484-491.
29. Hallander HO, Gustafsson L, Ljungman M, et al. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 31/2-61/2 years after the third vaccine dose. Vaccine 2005; 23: 5359-5364.